Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quantitative Unified Assessment of Novel Triplet Therapy and Unconventional Maintenance With Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial

NCT07717099 is registered in ClinicalTrials.gov with Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD as lead sponsor.

NCT NCT07717099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07717099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Quantitative Unified Assessment of Novel Triplet Therapy and Unconventional Maintenance With Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial
Lead sponsor
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2029
Enrollment
50 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone-sensitive prostate cance